Overview
CANSINOBIO (6185)
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Ad5-nCoV for Inhalation vacci...
- Open
- 23.980
- High
- 23.980
- Low
- 23.020
- Prev. Close
- 23.780
- Volume
- 1.62M
- Turnover
- 37.73M
- Avg Price
- 23.250
- Bid/Ask Ratio
- -33.33%
- Amplitude
- 4.04%
- 52wk High
- 46.780
- Volume Ratio
- 2.71
- Turnover Ratio
- 1.22%
- 52wk Low
- 19.220
- HK Mkt Cap
- 3.10B
- Market CapHKD
- 5.77B
- P/ETTM
- 166.52
- P/EDynamic
- 227.87
- P/EStatic
- --
- EPSTTM
- 0.140
- EPSDynamic
- 0.102
- EPSStatic
- --
- BVPS
- 23.61
- P/B
- 0.99
- HK Shares
- 132.67M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 247.04M
- Min lot size
- 200
- Currency
- HKD
CANSINOBIO Analyst Rating
View moreForecast & Rating
Oct 29, 2026- Strong buy75.00%
- Buy25.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 3
- Buy
- 1
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
CanSino Biologics declined 1.85% today, extending recent downward pressure driven by profit-taking and deteriorating fundamentals. Q3 results revealed revenue declined 6.3% sequentially to HKD 389 million while growing 14.71% YoY, though net profit fell 34.79% YoY to HKD 19.9 million as net margin contracted sharply from 11.04% last quarter to 5.12%. The stock has retreated 50.11% from its 52-week high of HKD 46.78 and is down 33.24% year-to-date, trading below both the 20-day moving average (26.76) and 60-day moving average (29.36). While broker consensus maintains price targets above current levels, an elevated PE of 166x combined with YoY profit decline creates valuation tension limiting near-term upside.
- Nov, 13
CanSino Biologics fell approximately 8% today, extending recent declines. Q3 revenue rose 14.71% year-over-year to HK$389 million, but net profit declined sharply by 34.79% to HK$19.9 million, with net margins compressing to 5.12% from Q2's 11.04%, signaling deteriorating earnings quality. The stock has dropped 49.17% from its 52-week high and is down 31.98% year-to-date, while trading at a stretched 169.66x PE valuation relative to current profitability. Despite recent positive Phase II data for the company's polio vaccine, market skepticism about near-term profit recovery appears to be driving profit-taking sentiment.
- Nov, 12
CanSino Biologics declined about 3% today, primarily reflecting profit headwinds from Q3 earnings—while 9-month revenue grew 27% year-over-year to 389M HKD (Q3: +14.7% YoY), net profit slumped dramatically from 45.9M HKD in Q2 to 19.9M HKD in Q3, a 57% sequential drop, with margins compressing from 11% to 5.1%. Intraday volatility was pronounced: the stock hit a high of 26.90 in the morning session before tumbling to a low of 25.62 in afternoon trading, closing at 26.00—signaling market concern over profit quality. On the positive side, phase II data from the polio vaccine trial came out favorably, and the latest weekly recap shows most brokers maintaining a buy rating. From a valuation lens, the stock has declined 26% year-to-date from the 34.96 opening and is now 45% below its 52-week high of 46.78, trading below the 60-day moving average of 29.50. Near-term profit-taking pressure persists, though longer-term catalysts continue to accumulate.
- Nov, 11
CanSino Biologics declined 1.69% to HKD 26.7 today, primarily due to profit-taking after a weekly gain of 3.81%. Year-to-date, the stock has fallen 23.63%, trading below both its 20-day (27.62) and 60-day (29.47) moving averages, having retreated 43% from its 52-week high of HKD 47.2. Q3 revenue reached HKD 389 million, up 14.71% year-over-year, but net profit of HKD 19.9 million declined 34.79% YoY, with net margin compressing from Q2's 11.04% to 5.12%, signaling profitability headwinds. The company reported positive Phase II immunization data for its polio vaccine candidate, and nine-month cumulative revenue and net profit grew 27% and 12.8% YoY respectively, earning broad broker support. Valued at a trailing PE of 190x, the current pullback reflects both profit-taking and caution on earnings recovery, though upcoming catalyst news from vaccine trials may offer support.
- Nov, 10
CanSino Biologics rose 2.3% to close at HK$27.16, with a weak morning session followed by strong afternoon rebound. The gain reflects improving fundamentals: nine-month revenue grew 27% year-over-year, while net profit expanded 12.8% YoY; Q3 operating profit surged 78.58% YoY to HK$73 million, demonstrating strengthened operational efficiency. Positive Phase II trial interim data from the polio vaccine candidate and broad 'buy' consensus from research brokers further supported the recovery. Nevertheless, Q3 net profit declined 34.79% YoY, indicating profitability pressures persist. Trading at 193x PE, down 43% from the 52-week high of HK$47.8, and off 22.3% year-to-date, valuation still appears lofty relative to near-term earnings power.
News
PUBT · CanSino Biologics Wins China Approval for Td5cp Vaccine Trial in Children Aged 4-5
Weekly Review · Weekly Recap | CANSINOBIO -10.4%, consensus target above spot
Market Movers · CanSino Biologics falls 6% in Hong Kong trading
Weekly Review · Weekly Recap | CANSINOBIO +3.81%, most brokers rate it buy
Market Movers · CanSino Biologics climbs 6%
Market Movers · CanSino Biologics climbs 6% on Q3 profit turnaround
